➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: May 24, 2020

DrugPatentWatch Database Preview

Litigation Details for Bayer Schering Pharma AG v. Teva Pharmaceuticals USA, Inc. (N.D. Ill. 2010)

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Bayer Schering Pharma AG v. Teva Pharmaceuticals USA, Inc. (N.D. Ill. 2010)

Docket   Start Trial Date Filed 2010-06-15
Court District Court, N.D. Illinois Date Terminated 2010-06-29
Cause 35:271 Patent Infringement Assigned To Virginia Mary Kendall
Jury Demand Plaintiff Referred To
Patents 5,798,338
Attorneys Adam K Mortara; Bradley C. Graveline; George Carter Lombardi; Matthew Raymond Ford; Michael Keenan Nutter; Paul J Skiermont; Paul R. Garcia; Peter Benjamin Bensinger , Jr.
Firms Bartlit Beck Herman Palenchar & Scott; Bartlit Beck Herman Palenchar and Scott LLP; Kirkland & Ellis LLP (Chicago); Michael Best and Friedrich; Skiermont Puckett LLP; Winston and Strawn LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Bayer Schering Pharma AG v. Teva Pharmaceuticals USA, Inc.
The small molecule drugs covered by the patent cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Bayer Schering Pharma AG v. Teva Pharmaceuticals USA, Inc. (N.D. Ill. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-06-15 1 PATENT-IN-SUIT 20. The patent-in-suit is U.S. Patent No. 5,798,338. The ’338 patent…: CLAIM FOR PATENT INFRINGEMENT OF UNITED STATES PATENT NO. 5,798,338 29. …ethinylestradiol is the subject of U.S. Patent No. 5,798,338, as discussed in greater detail below. …contributing to the infringement by others of U.S. Patent No. 5,798,338 in this District, and elsewhere in the United…; and from further infringement of U.S. Patent No. 5,798,338; 2. A judgment and order preliminarily External link to document
2010-06-15 12 product also infringe Bayer’s U.S. Patent No. 5,798,338 (“the ’338 Patent”) on the betadex formulation. Even…product, the Patent Act provides that Teva’s offers to sell directly infringe Bayer’s patent. Bayer…These efforts resulted in the ’338 patent. Bayer’s ’338 patent discloses a method and pharmaceutical…infringes the asserted claims of the [] patent and that the patent will likely withstand [the defendant’…infringes claim 1 of the ’338 Patent Claim 1 of the ’338 Patent covers: A pharmaceutical External link to document
2010-06-16 28 infringes one or more claims of U.S. Patent No. 5,798,338 (the"“338 patent”). III. Wholesalers, Distributors… has twelve patented products in various stages of development and nine additional patents pending. Therapeutic…healthcare company in 2003. The company owns twelve patents and is focused on the development, licensing and…on the marketing, licensing and divestiture of patented prescription and over-the-counter healthcare products…tactics which slowed generic erosion of products off patent and provided $10 5+ " ' ` million in External link to document
2010-06-16 29 infringes one or more claims of U.S. Patent No. 5,798,338 (the “‘338 patent”). II. Physicians Do Not Prescribe…2010 29 June 2010 1:10-cv-03697 830 Patent Plaintiff District Court, N.D External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.